Clinical Trials · NCT07745504

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Name: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Not Yet RecruitingPhase 3Semaglutide Cagrilintide

Phase: Phase 3
Recruitment status: Not Yet Recruiting
Sponsor: Novo Nordisk A/S
Enrollment: 285
Start date: Aug 2026
Locations: 36 sites, 6 countries
Primary endpoint: Relative change in body weight

View Semaglutide compound reference